Chemomab Therapeutics (CMMB) Free Cash Flow (2017 - 2023)
Chemomab Therapeutics (CMMB) posted Free Cash Flow of -$3.7 million for Q4 2023, up 28.71% on a QoQ basis from -$5.2 million in Q3 2023, and up 36.23% year-over-year from -$2.7 million in Q4 2022.
Chemomab Therapeutics (CMMB) Free Cash Flow (2017 - 2023) Analysis & Trends
Chemomab Therapeutics' Free Cash Flow history runs 7 years deep, the most recent figure standing at -$3.7 million for Q4 2023.
- Quarterly Free Cash Flow rose 36.23% year-over-year to -$3.7 million in Q4 2023, while the trailing twelve-month figure through Sep 2024 was -$3.7 million (up 85.53% YoY) and the FY2025 annual result came in at -$11.1 million, up 27.64% from the prior year.
- Free Cash Flow was -$3.7 million for Q4 2023 at Chemomab Therapeutics, up from -$5.2 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$880000.0 in Q2 2020 and bottomed at -$7.5 million in Q2 2023.
- A 5-year average of -$3.9 million and a median of -$3.7 million in 2022 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2020 — Free Cash Flow jumped 77.14% — and 2021, when it sank 548.75%.
- Chemomab Therapeutics' Free Cash Flow stood at -$6.1 million in 2019, then soared by 74.4% to -$1.6 million in 2020, then sank by 94.6% to -$3.0 million in 2021, then sank by 92.8% to -$5.8 million in 2022, then surged by 36.23% to -$3.7 million in 2023.
- Business Quant data shows CMMB's Free Cash Flow at -$3.7 million in Q4 2023, -$5.2 million in Q3 2023, and -$7.5 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.49 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 158.09 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -354.95 Mn |
| 10 | Chemomab Therapeutics | 704.11 Mn | 693.75 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -3.72 Mn |
| Dec 31, 2023 | -3.72 Mn |
| Sep 30, 2023 | -5.22 Mn |
| Sep 30, 2023 | -5.22 Mn |
| Jun 30, 2023 | -7.48 Mn |
| Jun 30, 2023 | -7.48 Mn |
| Mar 31, 2023 | -7.19 Mn |
| Mar 31, 2023 | -7.19 Mn |
| Dec 31, 2022 | -5.84 Mn |
| Dec 31, 2022 | -5.84 Mn |
| Sep 30, 2022 | -5.21 Mn |
| Sep 30, 2022 | -5.21 Mn |
| Jun 30, 2022 | -5.66 Mn |
| Jun 30, 2022 | -5.66 Mn |
| Mar 31, 2022 | -3.73 Mn |
| Mar 31, 2022 | -3.73 Mn |
| Dec 31, 2021 | -3.03 Mn |
| Dec 31, 2021 | -3.03 Mn |
| Sep 30, 2021 | -2.58 Mn |
| Sep 30, 2021 | -2.58 Mn |